Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Dupixent
Dupixent
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Fierce Pharma
Sun, 03/26/23 - 11:30 pm
Sanofi
Regeneron
Dupixent
COPD
Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Fierce Pharma
Thu, 03/23/23 - 11:44 am
Sanofi
Regeneron
Dupixent
COPD
clinical trials
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Mon, 03/20/23 - 10:06 am
Sanofi
Regeneron
Dupixent
COPD
Sanofi and Regeneron face a high-risk test for Dupixent
EP Vantage
Fri, 02/17/23 - 10:20 am
Sanofi
Regeneron
Dupixent
COPD
clinical trials
Dupixent kicks off 2023 as top pharma brand for ad impressions
Medical Devices and Diagnostics Industry
Mon, 02/6/23 - 06:13 pm
Sanofi
Dupixent
asthma
pharma advertising
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Fierce Pharma
Mon, 02/6/23 - 10:58 am
Sanofi
Dupixent
earnings
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
JPM23: Sanofi has reached the 'steady state' Paul Hudson envisioned years ago, CEO says
Fierce Pharma
Wed, 01/11/23 - 10:54 am
JPMHC 2023
Sanofi
Paul Hudson
Pharma CEOs
Dupixent
What This Drug News Could Mean for Sanofi Shareholders
Motley Fool
Sun, 01/8/23 - 10:13 pm
Sanofi
Dupixent
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
Fierce Pharma
Thu, 12/1/22 - 10:43 am
Regeneron
Sanofi
Dupixent
UK
side effects
Dupixent nears EU approval for rare skin disease prurigo nodularis
Pharmaphorum
Mon, 11/14/22 - 10:52 am
Sanofi
Regeneron
Dupixent
Europe
prurigo nodularis
Sanofi sees faster profit growth on Dupixent, flu vaccine demand
Yahoo/Reuters
Fri, 10/28/22 - 10:48 am
Sanofi
earnings
Dupixent
vaccines
Dupixent Shows Promise as First Treatment for Childhood EoE
BioSpace
Wed, 10/12/22 - 10:33 am
Dupixent
Sanofi
Regeneron
pediatric
clinical trials
eosinophilic esophagitis
FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis
Pharmaceutical Business Review
Thu, 09/29/22 - 10:05 am
Sanofi
Regeneron
Dupixent
prurigo nodularis
FDA
Sanofi’s asthma therapy shows consistent safety profile in Phase III trial
Clinical Trials Arena
Tue, 09/6/22 - 05:06 pm
Sanofi
Dupixent
pediatric
clinical trials
severe asthma
asthma
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
BioSpace
Wed, 08/3/22 - 09:19 pm
Regeneron
earnings
COVID-19
Eylea
Dupixent
Regeneron, Sanofi Look to Extend Dupixent into Young Kids with Eosinophilic Esophagitis
BioSpace
Thu, 07/14/22 - 11:49 am
Regeneron
Sanofi
Dupixent
pediatric
eosinophilic esophagitis
Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA
Motley Fool
Mon, 06/27/22 - 10:12 am
Sanofi
Regeneron
FDA
Dupixent
eosinophilic esophagitis
FDA approves Sanofi and Regeneron’s Dupixent for atopic dermatitis in young children
Pharmaceutical Business Review
Wed, 06/8/22 - 10:44 am
Sanofi
Regeneron
FDA
pediatric
atopic dermatitis
Dupixent
FDA grants speedy review to Dupixent rare skin disease
Pharmaforum
Tue, 05/31/22 - 10:43 am
Sanofi
Regeneron
Dupixent
prurigo nodularis
FDA
Pages
« first
‹ previous
1
2
3
4
5
6
7
next ›
last »